Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC Ml;KS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MknKbY5pcWKrdIOgeIhmKF[HR1[tbY5lfWOnZDDwdo9tcW[ncnH0bY9vKG:oIFjVWmVEew>? NEC2V3oyQDZ{MEO4Ni=>
HUVEC NVnPdY9iU2mwYYPlJIF{e2G7 MWPpcohq[mm2czDWSWdHNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKF[HR1\SMVIhcW5iSGXWSWMh[2WubIOge4l1cCCjbjDJR|UxKG:oIPMIwFghdk1? MnTYNVg3OjB|OEK=
MM MlnoT4lv[XOnIHHzd4F6 MoHJbY5pcWKrdIOgWmVITi2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCobISx M3rOPVE4OTZ2M{Oy
MM.1S NVzhdHBKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVXwXVJJOTBizsznM41N Mn3lbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? Mn\mNVcyPjR|M{K=
MM.1R Ml;zS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV:xNEDPxGdxbVy= MVnpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MXuxO|E3PDN|Mh?=
RPMI M{Tk[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYixNEDPxGdxbVy= M2LEfYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq MUmxO|E3PDN|Mh?=
Dox40 NGXUVWtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWOxNEDPxGdxbVy= MVnpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MYCxO|E3PDN|Mh?=
INA-6 Mne2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXzDOnZ{OTBizsznM41N MWrpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? M4nj[FE4OTZ2M{Oy
OPM2 M4PBdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{LXV|ExKM7:Zz;tUC=> MlrYbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MVGxO|E3PDN|Mh?=
U266 MlvJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVrZW3lsOTBizsznM41N NGjzTFNqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MnSyNVcyPjR|M{K=
MM.1S NF\scIxkgXSxdH;4bYNqfHliYYPzZZk> NFfITo0zOCEQvHevcWw> M3TURolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NEXIVJgyPzF4NEOzNi=>
MM.1R NH7sOlRkgXSxdH;4bYNqfHliYYPzZZk> MV:yNEDPxGdxbVy= MmCzbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= M4C4eVE4OTZ2M{Oy
RPMI NWnkd5lI[3m2b4TvfIlkcXS7IHHzd4F6 M1i5XFIxKM7:Zz;tUC=> M17mOIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NYq1e5F1OTdzNkSzN|I>
Dox40 MVnjfZRwfG:6aXPpeJkh[XO|YYm= NXvpTVROOjBizsznM41N MlTubY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= M3nUZVE4OTZ2M{Oy
INA-6 MVXjfZRwfG:6aXPpeJkh[XO|YYm= M3r4T|IxKM7:Zz;tUC=> M17NcIlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NVzIbYpFOTdzNkSzN|I>
OPM2 M1jWVIN6fG:2b4jpZ4l1gSCjc4PhfS=> NGnQd3EzOCEQvHevcWw> NG\1eJRqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs NVflOIhGOTdzNkSzN|I>
U266 M2jKeYN6fG:2b4jpZ4l1gSCjc4PhfS=> MVyyNEDPxGdxbVy= MVjpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu M33TW|E4OTZ2M{Oy
MM.1S MUTGeY5kfGmxbjDhd5NigQ>? MVPzeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? NEn6XVcyPzF4NEOzNi=>
MM.1R M3nXXWZ2dmO2aX;uJIF{e2G7 NGW2e2R{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= M1TvNlE4OTZ2M{Oy
Dox40 NVHWTmFyTnWwY4Tpc44h[XO|YYm= NEjOZ4x{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= MlXmNVcyPjR|M{K=
OPM2 MmmwSpVv[3Srb36gZZN{[Xl? M4fY[JN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= NEPp[ZUyPzF4NEOzNi=>
HBMEC M{DqfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MV3+NVAh|ryP NFfpcYxFVVOR NVPPco9LUUN3ME2xJO69VQ>? NF;GZoozOTB6MU[1Oi=>
HBMEC NVLVU3J3TnWwY4Tpc44h[XO|YYm= NWXLTlBMhjFizszN MlTnSG1UVw>? NWjBc|d3[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= M1TENlIyODhzNkW2
HBMEC MXvGeY5kfGmxbjDhd5NigQ>? MUX+NUDPxE1? M2\EV2ROW09? NHnQXndlcXO{dYD0d{B1cGViUnHzMXJi\i2HUlugdIF1cHejeTD0bJJwfWeqIHTlZ5Jm[XOnZDDwbI9{eGixconsZZRm\CCPRVuxM|Ih[W6mIFXST|EwOg>? NWnNeWJFOjFyOEG2OVY>
HBMEC MmfNSpVv[3Srb36gZZN{[Xl? NHH1U3N,OjBizszN NHnhfHJFVVOR M{HXO4Rqe3K3cITzJFUxLSCxZjD0eYJmKG[xcn3heIlwdiCjdDCxJO69VQ>? NYrIUGc2OjFyOEG2OVY>
MDA-MB-231 NWTN[4tFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NG[5dnp,OTBizszN MlLhSG1UVw>? MnrrTWM2OD13IN88US=> MWSyNVA5OTZ3Nh?=
MDA-MB-231 M1TUbmZ2dmO2aX;uJIF{e2G7 MVewMlUh|ryP MWTEUXNQ MX7pcohq[mm2czD0bIUhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5 M1jwfFIyODhzNkW2
MDA-MB-231 MlHVSpVv[3Srb36gZZN{[Xl? NGTROnQ2KM7:TR?= MoOzSG1UVw>? M3fDc4lv\HWlZYOgZUBk\WyuLXP5Z4xmKGG{cnXzeC=> NUfxXGN{OjFyOEG2OVY>
J82 MlnLZ5l1d3SxeHnjbZR6KGG|c3H5 M323[J4yOCEQvF2= MXfEUXNQ MVLJR|UxRTJ2LkW3JO69VQ>? MkPHNlE2Ojl7MEC=
T24 Ml3sZ5l1d3SxeHnjbZR6KGG|c3H5 NVP5UHBmhjFyIN88US=> NXjQfZhETE2VTx?= NYjaeWgzUUN3ME21Nk41PSEQvF2= NGmyNVAzOTV{OUmwNC=>
HT1376 NFjhNVNkgXSxdH;4bYNqfHliYYPzZZk> M{XkeJ4yOCEQvF2= NHXWS|FFVVOR NILhOpdKSzVyPUK4MlIyKM7:TR?= MWiyNVUzQTlyMB?=
RT4 NH7sXmlkgXSxdH;4bYNqfHliYYPzZZk> MlrkglExKM7:TR?= MlXSSG1UVw>? M17ERWlEPTB;NT6xOEDPxE1? M4fYOVIyPTJ7OUCw
CRL1749 MX\jfZRwfG:6aXPpeJkh[XO|YYm= NVz0SGczhjFyIN88US=> MUPEUXNQ MY\JR|UxRTJ{Lk[5JO69VQ>? MXSyNVUzQTlyMB?=
HTB9 NU\xPJh[[3m2b4TvfIlkcXS7IHHzd4F6 M4jZZp4yOCEQvF2= NYjjPGlYTE2VTx?= NYXsbVN1UUN3ME2xNU45PCEQvF2= MXSyNVUzQTlyMB?=
Sup MVLjfZRwfG:6aXPpeJkh[XO|YYm= NWP6UJB6hjFyIN88US=> NICybG1FVVOR NE[5eJpKSzVyPUWzMlMzKM7:TR?= NEXYTZAzOTV{OUmwNC=>
HTB3 Ml3TZ5l1d3SxeHnjbZR6KGG|c3H5 NFu1eIZ,OTBizszN M3OyPWROW09? Mmr4TWM2OD1zND6xOkDPxE1? MXiyNVUzQTlyMB?=
CEC MXjGeY5kfGmxbjDhd5NigQ>? NI\Xe5F,OTBizsznM41N NI\hZ3hFVVOR Mn30[I94di2{ZXf1cIF1\XNiVlXHSkBt\X[nbIO= NVj5bnVOOjF4MkC4NlI>
RPE M16wcWZ2dmO2aX;uJIF{e2G7 MXj+NVAh|rypL33M NEjJeZBFVVOR NEntNG9ld3ewLYLl[5Vt[XSnczDWSWdHKGyndnXsdy=> MYWyNVYzODh{Mh?=
CEC NV7O[pBCTnWwY4Tpc44h[XO|YYm= MorDglUh|rypL33M MXTEUXNQ M17S[IJtd2OtczDlcoRwfGinbHnhcEBk\WyuIH3p[5JifGmxbh?= M1vnOlIyPjJyOEKy
5637 NEflUIxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2rpW2ROW09? NYfE[XJwUUN3ME2xOU4x6oDLzszN M{DVeFI{QDh5NkC1
J82 MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWfxc45oTE2VTx?= NEfoTXRKSzVyPUG4MlTjiIoQvF2= MnXZNlM5QDd4MEW=
5637 NFL3cYtCfXSxcHjh[5kh[XO|YYm= M2LKRlIxKM7:TR?= MlG5SG1UVw>? NITXPXJ1emmpZ3Xyd{B1cGViYYX0c5Bp[WerYzDwdo9k\XO| NH7QXpczOzh6N{[wOS=>
J82 NW\5TYFISXW2b4DoZYd6KGG|c3H5 NVriUHltOjBizszN MX;EUXNQ NXP1[XZFfHKrZ3fldpMhfGinIHH1eI9xcGGpaXOgdJJw[2W|cx?= MnrxNlM5QDd4MEW=
5637 M2nrbWZ2dmO2aX;uJIF{e2G7 NH;w[GMzOCEQvF2= MlXUSG1UVw>? MYTpcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO= NITX[3AzOzh6N{[wOS=>
J82 MVjGeY5kfGmxbjDhd5NigQ>? NGCydWkzOCEQvF2= MlHTSG1UVw>? M{W2WYlv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> M3;BdlI{QDh5NkC1
5637 NI\JPWJHfW6ldHnvckBie3OjeR?= Mn\BNlAh|ryP NIC4U3FFVVOR M361Xolv\HWlZYOgcJl{d3OxbXWgZYx1\XKjdHnvckBidmRiaX7obYJqfHNiQ1KgZYN1cX[rdIm= Ml;NNlM5QDd4MEW=
J82 NYXSTnBjTnWwY4Tpc44h[XO|YYm= MVqyNEDPxE1? NIT0XZhFVVOR NIHrd|BqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 NVHTdYZSOjN6OEe2NFU>
KATO-II M1jH[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYfIOplGPSEQvF2= NUfJcHFNTE2VTx?= MWTicI9kc3NicILvcIln\XKjdHnvci=> MUeyOVI1QTV3Nx?=
OCUM-2M MnXMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MW[1JO69VQ>? NF\1dZBFVVOR NHf5cWxjdG:la4OgdJJwdGmoZYLheIlwdg>? MWWyOVI1QTV3Nx?=
SNU-16 M{juUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mn2wOUDPxE1? NInGXnBFVVOR MVnicI9kc3NicILvcIln\XKjdHnvci=> NXO5bJRiOjV{NEm1OVc>
HSC-39 NFvwXmNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2HxW|Uh|ryP MYPEUXNQ Ml\LZoxw[2u|IIDyc4xq\mW{YYTpc44> MoXKNlUzPDl3NUe=
KATO-II NXrjSI9[[3m2b4TvfIlkcXS7IHHzd4F6 Ml;NglExKM7:TR?= NYTpcnJUTE2VTx?= M2i5bWlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O MUOyOVI1QTV3Nx?=
OCUM-2M NYfwXXk3[3m2b4TvfIlkcXS7IHHzd4F6 NVq1PZJ5hjFyIN88US=> NIPWe2tFVVOR NWnINZd{UUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= MVeyOVI1QTV3Nx?=
SNU-16 NHnQRm9kgXSxdH;4bYNqfHliYYPzZZk> MWL+NVAh|ryP MnLJSG1UVw>? MVnJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? NHTVNGMzPTJ2OUW1Oy=>
HSC-39 M37vS4N6fG:2b4jpZ4l1gSCjc4PhfS=> MkDhglExKM7:TR?= MXLEUXNQ M4j1bGlEPTB;MD6xJJRwKDJwMDFOwI1wdC:O NXrKV2NuOjV{NEm1OVc>
NIH 3T3 M3fmPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVftbYhzhjFyIN88US=> NGDvZ3hFVVOR M3z5fYlvcGmkaYTzJINmdGxiZ4Lve5RpKGGwZDDjc4xwdnliZn;ycYF1cW:w NFzG[oEzPTJ2OUW1Oy=>
KATO-III MV3GeY5kfGmxbjDhd5NigQ>? MVyxJO69VQ>? MonHSG1UVw>? NWLEXnJ5cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> M{DENVI2OjR7NUW3
OCUM-2M M{XGPWZ2dmO2aX;uJIF{e2G7 MmrlNUDPxE1? NHHEXHhFVVOR M3TXS4lv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= M1;xN|I2OjR7NUW3
KATO-III NXLPZolPSXCxcITvd4l{KGG|c3H5 MVKxJO69VQ>? MVnEUXNQ NH;hc2hqdmS3Y3XzJIFxd3C2b4Ppdy=> MV6yOVI1QTV3Nx?=
OCUM-2M NYnuW2FlSXCxcITvd4l{KGG|c3H5 Mk\RNUDPxE1? M{HIXmROW09? NULJbnY5cW6mdXPld{BieG:ydH;zbZM> NXvEco4zOjV{NEm1OVc>
KATO-III M{nje2Z2dmO2aX;uJIF{e2G7 NWfTNmQ6OSEQvF2= MlvPSG1UVw>? MYjpcohq[mm2czDGS2ZTOiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nJI1wdGWldXzldy=> MWKyOVI1QTV3Nx?=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID